Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | FPR2 | P25090 | 2/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.54 |
| ▸ | MME | P08473 | 2/20 | 0.53 |
| ▸ | CPA1 | P15085 | 1/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 4/20 | 0.49 |
| ▸ | MMP9 | P14780 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71781 | 1.00 | ACE (0.56) | ACENPSR1FPR2ECE1MME | |
| SCHEMBL933401 | 1.00 | ACE (0.56) | ACENPSR1FPR2ECE1MME | |
| SCHEMBL8823272 | 0.86 | ACE (0.58) | ACEMMECPA1NAALAD2L3MBTL1 | |
| SCHEMBL21326281 | 0.86 | EPHX1 (0.49) | ACENPSR1FPR2ECE1CPA1 | |
| SCHEMBL21326284 | 0.86 | EPHX1 (0.49) | ACENPSR1FPR2ECE1CPA1 | |
| SCHEMBL8823270 | 0.86 | ACE (0.58) | ACEMMECPA1NAALAD2L3MBTL1 | |
| SCHEMBL29022675 | 0.85 | FPR2 (0.50) | ACENPSR1FPR2MMEMMP2 | |
| SCHEMBL6402000 | 0.85 | SLC7A5 (0.56) | ACEALDH1A1 | |
| SCHEMBL6401999 | 0.85 | SLC7A5 (0.56) | ACEALDH1A1 | |
| SCHEMBL5772094 | 0.83 | ATM (0.57) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1879 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115165948-B | NMR-based Arf 6-specific guanylate exchange factor GEF activity detection method and application thereof | 中国科学院合肥物质科学研究院 | 2025-01-10 | — | — | CN | claimed |
| EP-4274838-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LTD (GB) | 2024-09-25 | — | — | EP | claimed |
| US-20240108738-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LIMITED (GB) | 2024-04-04 | — | — | US | claimed |
| US-11904020-B2 | Bicyclic peptide ligands specific for TREM2 | BICYCLETX LIMITED (GB) | 2024-02-20 | — | — | US | claimed |
| CN-117529489-A | Bicyclic peptide ligands specific for NK cells | 拜斯科技术开发有限公司 | 2024-02-06 | — | — | CN | claimed |
| EP-4308586-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | BicycleTX Limited (GB) | 2024-01-24 | — | — | EP | claimed |
| US-20240011009-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2024-01-11 | — | — | US | claimed |
| CN-117337295-A | Bicyclic peptide ligands specific for TREM2 | 拜斯科技术开发有限公司 | 2024-01-02 | — | — | CN | claimed |
| EP-4274838-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| US-20230220589-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2023-07-13 | — | — | US | claimed |
| EP-3334759-A1 | LACTOFERRIN FRAGMENT FOR THE USE AS ANTIBACTERIAL AND ANTIVIRAL AGENT | Farmagens Health Care Srl (IT) | 2018-06-20 | — | — | EP | claimed |
| CN-108047304-A | - 7 selective depressant of metalloproteinases and its preparation method and application | 延边大学 | 2018-05-18 | — | — | CN | claimed |
| WO-2017025846-A1 | LACTOFERRIN FRAGMENT FOR THE USE AS ANTIBACTERIAL AND ANTIVIRAL AGENT | FARMAGENS HEALTH CARE SRL (IT) | 2017-02-16 | — | — | WO | claimed |
| US-20030143664-A1 | Products of manufacture and processes for peptide synthesis | DIVERSA CORPORATION (US) | 2003-07-31 | — | — | US | claimed |
| WO-2003048189-A2 | PRODUCTS OF MANUFACTURE AND PROCESSES FOR PEPTIDE SYNTHESIS | DIVERSA CORPORATION (US) | 2003-06-12 | — | — | WO | claimed |
| EP-0950046-B1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | NAEJA PHARMACEUTICAL INC (CA) | 2002-04-10 | — | — | EP | claimed |
| US-6232305-B1 | ANTICANCER AGENTS; BONE DISORDERS; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS | NAEJA PHARMACEUTICAL INC. (CA) | 2001-05-15 | — | — | US | claimed |
| EP-0950046-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (CA) | 1999-10-20 | — | — | EP | claimed |
| WO-1999050283-A1 | HIGH THROUGHPUT SCREENING ASSAYS FOR MODULATORS OF STAT4 AND STAT6 ACTIVITY | TULARIK INC. (US) | 1999-10-07 | — | — | WO | claimed |
| WO-1998012176-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (US) | 1998-03-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11904020-B2 | Bicyclic peptide ligands specific for TREM2 | APP, TIMCC, ADM2 | ACE 1201/4885NPSR1 525/4885FPR2 5/4885 |
| US-20240108738-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | PBK, KLRK1, MICA | ACE 1945/4885NPSR1 352/4885FPR2 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.